Literature DB >> 18575194

Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania.

Geofrey R Somi1, Tabitha Kibuka, Karidja Diallo, Tulli Tuhuma, Diane E Bennett, Chunfu Yang, Charles Kagoma, Eligius F Lyamuya, Roland O Swai, Sidibe Kassim.   

Abstract

BACKGROUND: In resource-limited settings where antiretroviral treatment (ART) access is being scaled-up, the World Health Organization (WHO) recommends surveillance of transmitted HIV drug resistance (HIVDR). We used the WHO HIVDR threshold survey method to assess transmitted HIVDR in Dar es Salaam where ART was introduced in 1995 and where approximately 11,000 people are currently on ART.
METHODS: From November 2005 to February 2006, dried blood spot (DBS) specimens were made from remnant specimens collected during the national HIV serosurvey from 60 primagravidas <25 years old attending six antenatal clinics for routine syphilis testing. Genotyping was performed at the Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Protease and reverse transcriptase drug resistance mutations were identified using the Stanford University HIV drug resistance database. We used the National Institutes of Health genotyping tool for HIV-1 subtyping. HIVDR prevalence categorization was based on the WHO threshold survey binomial sequential sampling method.
RESULTS: Among the 60 eligible specimens collected, 50 DBS were successfully amplified using RT-PCR. Sequencing was performed on the first 39 specimens: 13 (33.3%) were subtype A1, 13 (33.3%) subtype C, and 4 (10.3%) subtype D, the remainder differed in the closest subtype based on protease versus reverse transcriptase. No resistance mutations were seen; HIVDR to all drug classes was categorized as <5%.
CONCLUSIONS: Our survey indicates that prevalence of transmitted HIVDR among recently infected pregnant women in Dar es Salaam is low (<5/%). The survey should be repeated during the next HIV sentinel survey in Dar es Salaam and extended to other regions where ART is being scaled up.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18575194

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  27 in total

1.  Surveillance of transmitted drug-resistant HIV among young pregnant women in Ouagadougou, Burkina Faso.

Authors:  Antoine Somda; Lassana Sangare; Monique Soro; Saydou Yameogo; Babou Bazie; Françoise Bigirimana; Silvia Bertagnolio; Martine Peeters; Fatima Mouacha; Ana Maria Rivera; Michael R Jordan; Marie-Joseph Sanou
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

2.  Prevalence of transmitted HIV drug resistance among newly diagnosed antiretroviral therapy-naive pregnant women in Lilongwe and Blantyre, Malawi.

Authors:  Nellie Wadonda-Kabondo; Richard Banda; Kundai Moyo; Maurice M'bang'ombe; Mabvuto Chiwaula; Carol Porter; Michael R Jordan
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

3.  Antiretroviral drug resistance surveillance among treatment-naive human immunodeficiency virus type 1-infected individuals in Angola: evidence for low level of transmitted drug resistance.

Authors:  Inês Bártolo; Cheila Rocha; José Bartolomeu; António Gama; Marlene Fonseca; Ana Mendes; Filipa Cristina; Sven Thamm; Marta Epalanga; Patrícia Cavaco Silva; Nuno Taveira
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

4.  Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia.

Authors:  Praphan Phanuphak; Sunee Sirivichayakul; Awachana Jiamsakul; Somnuek Sungkanuparph; Nagalingeswaran Kumarasamy; Man Po Lee; Thira Sirisanthana; Pacharee Kantipong; Christopher Lee; Adeeba Kamarulzaman; Mahiran Mustafa; Rossana Ditangco; Tuti Merati; Winai Ratanasuwan; Thida Singtoroj; Rami Kantor
Journal:  J Acquir Immune Defic Syndr       Date:  2014-05-01       Impact factor: 3.731

Review 5.  Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update.

Authors:  Reuben Granich; Siobhan Crowley; Marco Vitoria; Caoimhe Smyth; James G Kahn; Rod Bennett; Ying-Ru Lo; Yves Souteyrand; Brian Williams
Journal:  Curr Opin HIV AIDS       Date:  2010-07       Impact factor: 4.283

Review 6.  Drug resistance surveillance in resource-poor settings: current methods and considerations for TB, HIV, and malaria.

Authors:  Bethany L Hedt; Miriam K Laufer; Ted Cohen
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

7.  The prevalence of transmitted drug resistance in newly diagnosed HIV-infected individuals in Croatia: the role of transmission clusters of men who have sex with men carrying the T215S surveillance drug resistance mutation.

Authors:  Ivana Grgic; Snjezana Zidovec Lepej; Maja M Lunar; Mario Poljak; Adriana Vince; Ivana Baca Vrakela; Ana Planinic; Katja Seme; Josip Begovac
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-04       Impact factor: 2.205

8.  Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a rural HIV clinic in Kenya.

Authors:  Amin S Hassan; Shalton M Mwaringa; Clare A Obonyo; Helen M Nabwera; Eduard J Sanders; Tobias F Rinke de Wit; Patricia A Cane; James A Berkley
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-11       Impact factor: 2.205

9.  Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

Authors:  Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

10.  Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study.

Authors:  Mison Dahab; Salome Charalambous; Alan S Karstaedt; Katherine L Fielding; Robin Hamilton; Lettie La Grange; Gavin J Churchyard; Alison D Grant
Journal:  BMC Public Health       Date:  2010-07-22       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.